09.03.2023 13:19:30
|
ANI Pharma Guides FY23 Adj. EPS Below Estimates, But Revenues Above - Update
(RTTNews) - While reporting financial results for the fourth quarter on Thursday, biopharmaceutical company ANI Pharmaceuticals, Inc. (ANIP) initiates adjusted earnings and net revenue guidance for the full-year 2023.
For fiscal 2023, the company now projects adjusted earnings in a range of $2.09 to $2.59 per share on net revenues between $360 million and $385 million, with purified cortrophin gel revenue at $80 million to $90 million.
On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.62 per share on revenues of $352.49 million for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Biosante Pharmaceuticals Incmehr Nachrichten
07.11.24 |
Ausblick: Biosante Pharmaceuticals verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net) |
Analysen zu Biosante Pharmaceuticals Incmehr Analysen
Aktien in diesem Artikel
Biosante Pharmaceuticals Inc | 55,50 | 0,00% |
|